Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study

Raymond L. Benza, Athénaïs Boucly, Harrison W. Farber, Adaani E. Frost, Hossein Ardeschir Ghofrani, Marius M. Hoeper, Marc Lambelet, Claudia Rahner, Sameer Bansilal, Sylvia Nikkho, Christian Meier, Olivier Sitbon

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


BACKGROUND: Risk assessment is essential in pulmonary arterial hypertension (PAH) management. We investigated the effect of riociguat on REVEAL Lite 2 score, an abridged version of the REVEAL risk score, and its association with long-term outcomes in PATENT.

METHODS: PATENT-1 was a randomized, double-blind study of riociguat vs placebo in patients with PAH. In the PATENT-2 open-label extension, all patients received riociguat up to 2.5 mg three times daily (n = 396). REVEAL Lite 2 scores were calculated at baseline, PATENT-1 Week 12, and PATENT-2 Week 12, with patients stratified as low- (1-5), intermediate- (6-7), or high-risk (≥8). Kaplan-Meier and Cox proportional hazards analyses assessed association of riociguat with survival and clinical worsening-free survival (CWFS).

RESULTS: REVEAL Lite 2 score improved with riociguat 2.5 mg at PATENT-1 Week 12 (least-squares mean difference vs placebo: -0.8; p = 0.0004). More patients receiving riociguat 2.5 mg stabilized or improved risk stratum at PATENT-1 Week 12 vs placebo (p = 0.0005) and achieved low-risk status. REVEAL Lite 2 score at baseline and PATENT-1 Week 12 were associated with survival and CWFS (all p < 0.0001), as was change in score from baseline to Week 12 (p = 0.0002 and p < 0.0001, respectively). Survival and CWFS differed between risk strata at baseline (p < 0.0001) and PATENT-1 Week 12 (p < 0.0001).

CONCLUSIONS: This analysis confirms the risk-reduction benefits of riociguat in patients with PAH and further contributes to the validation of REVEAL Lite 2 in facilitating PAH risk assessment.

Original languageEnglish (US)
Pages (from-to)411-420
Number of pages10
JournalJournal of Heart and Lung Transplantation
Issue number3
StatePublished - Mar 2022


  • pulmonary arterial hypertension
  • riociguat
  • risk assessment
  • Double-Blind Method
  • Pyrazoles/therapeutic use
  • Humans
  • Risk Factors
  • Pulmonary Arterial Hypertension/drug therapy
  • Treatment Outcome
  • Pyrimidines/therapeutic use

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Transplantation
  • Pulmonary and Respiratory Medicine
  • Surgery


Dive into the research topics of 'Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study'. Together they form a unique fingerprint.

Cite this